Oppenheimer's top 50 small- and mid-cap Sell ideas

What happened

Oppenheimer technical analyst Ari Wald updated the firm's list of 50 top small- and mid-cap Sell ideas, flagging stocks with weaker technical trends across sectors. New additions include XPEL, Rhythm Pharmaceuticals, Novanta, Harmonic and Brookfield Infrastructure Partners.

Confirmed

Global impact / market context

Sell lists from brokerage firms can shape investor positioning, because clients may reduce holdings or avoid these names. The list is meant to stay market- and sector-neutral, so it reflects relative weakness rather than a broad bearish call.

Analyst inference

Oppenheimer balances equal numbers of Buy and Sell ideas to stay neutral. Its Momentum Overlay scores rank stocks 1 to 5, with 5 weakest, based on 6-, 9- and 12-month risk-adjusted returns, which means returns adjusted for price swings.

Analyst inference

What to watch

1. New Sell additions are XPEL, Rhythm Pharmaceuticals, Novanta, Harmonic and Brookfield Infrastructure Partners, joining existing names such as DraftKings, Carlyle Group, Rivian Automotive and TripAdvisor. Confirmed
2. Investors could compare each Sell idea's Momentum Overlay score, which is a 1-to-5 ranking of price strength, to decide which weak trends to act on or review. Proposed
3. Weaker technical trends could reflect company-specific pressure on revenue or costs, so watch upcoming earnings and guidance from these names for signs of fundamental deterioration. Analyst inference

Evidence

• seekingalpha.com